FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: A propensity score-adjusted analysis from two randomized clinical trials

Annals of Oncology

Volumn 27, Issue 5, 2016, Pages 843-849

  Cremolini, C ^a,b   Loupakis, F ^a,b   Masi, G ^a,b   Lonardi, S ^c   Granetto, C ^d   Mancini, M L ^e   Chiara, S ^f   Moretto, R ^a,b   Rossini, D ^a,b   Vitello, S ^g   Allegrini, G ^h   Tonini, G ⁱ   Bergamo, F ^c   Tomasello, G ^j   Ronzoni, M ^k   Buonadonna, A ^l   Bustreo, S ^m   Barbara, C ⁿ   Boni, L ^o   Falcone, A ^a,b  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d S CROCE E CARLE HOSPITAL   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g Neurology Unit   (Italy)

^h 'Felice Lotti' Hospital   (Italy)

ⁱ UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^j CREMONA HOSPITAL   (Italy)

^k SAN RAFFAELE HOSPITAL   (Italy)

^l CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^m MOLINETTE HOSPITAL   (Italy)

ⁿ Division of Medical Oncology   (Italy)

^o ISTITUTO TOSCANO TUMORI   (Italy)

more..

Author keywords

Bevacizumab; FOLFOXIRI; Metastatic colorectal cancer

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CONTINUOUS INFUSION; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPENSITY SCORE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL TIME; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COLORECTAL TUMOR; CONTROLLED STUDY; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LIVER TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 84964714901     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw052     Document Type: Article

References (23)

1. Cunningham D, Lang I, Marcuello E et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013; 14: 1077-1085.
2. Loupakis F, Cremolini C, Masi G et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014; 371: 1609-1618.
3. Cremolini C, Schirripa M, Antoniotti C et al. First-line chemotherapy for mCRC- a review and evidence-based algorithm. Nat Rev Clin Oncol 2015; 12: 607-619.
4. Fakih MG. Metastatic colorectal cancer: current state and future directions. J Clin Oncol 2015; 33: 1809-1824.
5. Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676.
6. Cremolini C, Loupakis F, Antoniotti C et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015; 16: 1306-1315.
7. Cremolini C, Loupakis F, Antoniotti C et al. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann Oncol 2015; 26: 1188-1194.
8. Kabbinavar FF, Hambleton J, Mass RD et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23: 3706-3712.
9. Tebbutt NC, Wilson K, Gebski VJ et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010; 28: 3191-3198.
10. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
11. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
12. Passardi A, Nanni O, Tassinari D et al. Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. Ann Oncol 2015; 26: 1201-1207.
13. Sobrero A, Ackland S, Clarke S et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in firstline metastatic colorectal cancer. Oncology 2009; 77: 113-119.
14. D'Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281.
15. Haukoos JS, Lewis RJ. The Propensity Score. JAMA 2015; 314: 1637-1638.
16. Loupakis F, Schirripa M, Caparello C et al. Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. Br J Cancer 2013; 108: 2549-2556.
17. Masi G, Loupakis F, Salvatore L et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010; 11: 845-852.
18. Stein A, Atanackovic D, Hildebrandt B et al. Upfront FOLFOXIRI + bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer. Br J Cancer 2015; 113: 872-877.
19. Hegewisch-Becker S, Graeven U, Lerchenmuller CA et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 2015; 16: 1355-1369.
20. Koeberle D, Betticher DC, von Moos R et al. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/ 06). Ann Oncol 2015; 26: 709-714.
21. Simkens LH, van Tinteren H, May A et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 2015; 385: 1843-1852.
22. Huiskens J, van Gulik TM, van Lienden KP et al. Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG). BMC Cancer 2015; 15: 365.
23. A phase II study to evaluate the surgical conversion rate in patients with RAS mutation-type receiving FOLFOXIRI +/- bevacizumab for unresectable colorectal liver-limited metastases; https://clinicaltrials.gov/ct2/show/NCT02350530 2015 (1 October 2015, date last accessed).